Hostname: page-component-78c5997874-dh8gc Total loading time: 0 Render date: 2024-11-05T02:32:35.853Z Has data issue: false hasContentIssue false
  • English
  • Français

Commentary: Who's Afraid of the RAC? Lessons from the Oversight of Controversial Science

Published online by Cambridge University Press:  01 January 2021

Jeffrey P. Kahn
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Symposium
Information
Journal of Law, Medicine & Ethics , Volume 37 , Issue 4 , Winter 2009 , pp. 685 - 687
Copyright
Copyright © American Society of Law, Medicine and Ethics 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Wolf, S. M., Gupta, R. and Kohlepp, P., “Gene Therapy Oversight: Lessons for Nanobiotechnology,” Journal of Law, Medicine & Ethics 37, no. 4 (2009): 659–684.CrossRefGoogle Scholar
Id.Google Scholar
Fredrickson, D. S., The Recombinant DNA Controversy (Washington, D.C.: American Society of Microbiology Press, 2001): at 278.CrossRefGoogle Scholar
Id.Google Scholar
See Wolf, et al., supra, note 1.Google Scholar
Scott, C., “What Stem Cell Therapy Can Learn from Gene Therapy,” Nature Reports Stem Cells (2008), published online September 4, 2008.CrossRefGoogle Scholar